NGM Biopharmaceuticals, Inc

Related records

Trials (27)

• A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
• A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19
• A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
• A Study of NGM621 in Participants With Geographic Atrophy
• Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
• An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
• Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
• Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants
• Phase 1 Study of NGM313 in Healthy Adult Participants
• Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
• Phase 2 Study of NGM282 in Patients With Type 2 Diabetes
• Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
• Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
• Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
• Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
• Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
• Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
• Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
• Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
• Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals